This observational study, called LiFT UP, aims to better understand the TP53 gene and its connection to Li-Fraumeni Syndrome (LFS), a condition that increases cancer risk. Researchers are collecting data and samples from people with a TP53 gene change (pathogenic or likely pathogenic variant) found in their blood or saliva, or those with a family history of such a change. The goal is to improve our understanding of cancer risks associated with TP53 variants, help families receive more accurate counseling, and find better ways to prevent, detect, and treat cancer. The study also explores TP53 variants found in the blood that are not inherited. Success for this study means creating a valuable collection of specimens and data over five years or until the study closes. The study plans to enroll about 1500 participants, but its current recruitment status is unclear.

Study design

This is an observational study with a planned enrollment of about 1500 participants. It is not testing a specific drug or treatment.

What's involved

You would provide access to your medical records and answer short questionnaires periodically. You may also be asked to provide blood, saliva, eyebrow hair, and tumor tissue samples, and to share study information with family members.

Compensation

Not stated in the trial record.

Follow-up

Participants will be in this study until it closes or they withdraw consent. The primary goal is to establish a repository of specimens and data, measured at 5 years or study closure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.